Table 2 |
|||
|
Use of palivizumab and resources saving during 2008-2009 campaign |
|||
|
Theoretical single use |
Real use with vial sharing |
Saving |
|
|
|
|||
|
50 mg vials |
67 |
16 |
51 |
|
|
|||
|
100 mg vials |
58 |
60 |
-2 |
|
|
|||
|
mg wasted |
3.176,88 |
777,08 |
2.399,80 |
|
|
|||
|
Value |
80.087,09€ |
56.706,92€ |
23.380,17€ |
|
|
|||
|
Coletta et al. Italian Journal of Pediatrics 2010 36:48 doi:10.1186/1824-7288-36-48 |
|||
